Furthermore, patient-reported SpA measures are known to differentiate poorly between symptoms related to SpA or CWP [48], with generally worse outcomes among patients with such comorbidity [49, 50], and poorer adherence to anti-TNF therapy was also recently reported in SpA patients with concurrent fibromyalgia [50]. This evidence concerns the gene TNF and fibromyalgia.